Treatment Rheumatoid Arthritis Baricitinib CAS 1187594-09-7 Raw Powder Materials

CAS: 1187594-09-7

MF: C16H17N7O2S

EINECS: 691-421-4

Specification​: 99% min Baricitinib 

Sample: Baricitinib Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Portal:https://henrikang.en.made-in-china.com/

Baricitinib Powder Usage and Synthesis:

Baricitinib Powder is an oral inhibitor of JAK kinase 1 and 2 that is commonly used in adults for the treatment of moderately to severely active rheumatoid arthritis (RA). For patients with rheumatoid arthritis who have not previously used a biologic DMARDS drug, Baricitinib CAS 1187594-09-7 may reduce the activity of the disease. Baricitinib Raw Materials It is an off-white or white crystalline powder, odorless and tasteless, slightly soluble in water, dissolved in hot water, insoluble in ethanol or acetone, and soluble in sodium hydroxide test solution.

Application/Function of Baricitinib Powder:

Baricitinib is a medication used to treat moderate to severe rheumatoid arthritis in adults. It works by blocking certain enzymes in the body that cause inflammation. Baricitinib is taken orally, usually once a day, and is available in tablet form. It is typically used in combination with other medications to treat rheumatoid arthritis. Baricitinib can have side effects, including an increased risk of infections, so it is important for patients to work closely with their healthcare provider while taking this medication.

• 1.For the treatment of moderately to severely active rheumatoid arthritis (RA) in adults who are intolerant to one or more antirheumatic drugs. baricitinib is currently in Phase II clinical use for the treatment of psoriasis, diabetic nephropathy, atopic dermatitis, and systemic lupus erythematosus.
• 2. Used in scientific research and chemical reagents

Mechanism of action of Baricitinib Powder:

Baricitinib (olumiant) is a selective JAK2 and JAK1 inhibitor with low potency against JanusKinase, jak3orTYK2. This kinase and its associated signal transducer and activator of transcription (JAK-STAT) are the major intracellular pathways that control the magnitude and duration of cytokine signaling to type I and type II cytokine receptors.

These receptors lack intrinsic enzymatic activity signaling that can be mediated; Janus kinase\signaling and activator of transcription is phosphorylated via JAK enzymes, leading to STAT activation. Several inflammatory factors are involved in the pathogenesis of RA, including IL-6, granulocyte macrophage colony-stimulating factor, and (GM-CSF) factor.

Interferon signaling is via the JAK-STAT signaling pathway. Therefore, JAK1 and JAK2 inhibitors target multiple RA-associated cytokine pathways, which may reduce the activation and proliferation of key immune cells in inflammatory cells. baricitinib has no effect on JAK3, which may be associated with common gamma-chain receptors. Common gamma-chain cytokines include IL-15 and IL-21, which primarily act to regulate lymphocyte activation, function and proliferation.

Preparation process of Baricitinib Powder.

Baricitinib (LY3009104, INCB028050) is a selective JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively, which are approximately 70 and 10-fold more selective than those used for JAK3 and Tyk2, with no inhibition of c-Met and Chk2.Phase 3.